{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 95 of 122', '16 INVESTIGATOR SIGNATURE', 'AIMMUNE THERAPEUTICS, INC.', 'Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children', 'and Adolescents: Real-World, Open-Label, Quality of Life Study', 'Signature of Agreement for ARC009 Protocol Amendment 1.0 - 11 Apr 2018', 'I have read this protocol and agree to conduct the study as outlined herein, in accordance', 'with the Declaration of Helsinki (2013), principles of Good Clinical Practice as described in', 'the International Council for Harmonisation guidelines, including the archiving of essential', 'documents, EU Directive 2001/20/EC (the Clinical Trials Regulation), EU Directive', '2005/28/EC (Good Clinical Practice Directive), and local applicable legislation including but', 'not limited to the UK SI 2004/1031 Medicines for Human Use (Clinical Trials)', 'Regulations 2004 as amended.', 'Print Study Site Name', 'Study Site Number', '(if known)', 'Print Investigator Name', 'Investigator Signature', 'Date']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 96 of 122', 'Appendix 1: Open-Label Food Challenge Procedures', 'An open-label food challenge (OLFC) is a procedure performed under medical supervision', 'by feeding a test food product (peanut) in measured, increasing doses. Food allergic', 'reactions can potentially develop and may be severe (eg, resulting in anaphylaxis).', 'Incremental dosing may reduce the risk of severe allergic reactions by allowing the', 'procedure to stop for medical treatment when a reaction becomes apparent. The acceptable', 'and safe procedures for study subjects participating in an OLFC as part of this protocol are', 'described herein; additional procedures may be required as specified in the protocol schedule', 'of activities.', 'The OLFCs conducted under this protocol will follow procedures consistent with the', 'Practical Allergy (PRACTALL) guidelines for safety, assessment, and scoring', '(Sampson, 2012).', 'The food challenge consists of peanut (defatted peanut flour mixture containing', 'approximately 33% peanut protein [wt/wt]) mixed in a vehicle (matrix) food. The peanut', 'flour mixture includes additional nonallergenic, powdered flavoring agents to help further', 'mask the distinctive flavor of peanut and a small amount of oat flour. The OLFC will use the', 'dosing schedule shown in Table 1.', 'Table 1: OLFC Challenge Doses', 'Dose Number', 'Peanut Protein Dose (mg)', 'Cumulative Peanut Protein (mg)', '1', '3', '3', '2', '10', '13', '3', '30', '43', '4', '100', '143', '5', '300', '443', '6', '600', '1043', '7', '1000', '2043', 'OLFC, open-label food challenge.', 'PROCEDURES', 'General Safety Considerations', 'A study physician will supervise all OLFCs.', 'Personnel involved in an OLFC must be specifically trained in the management of acute', 'allergic reactions.', 'All necessary medications for treatment of an allergic reaction and resuscitation equipment', 'must be readily available, including epinephrine, oxygen, antihistamines (both H1 and H2),', 'beta-adrenergic agonists, corticosteroids, and intravenous (IV) fluids.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 97 of 122', 'PREPARATION FOR THE OLFC', 'Before the Day of the OLFC', 'Contact the subject and parent/caregiver: Study site staff should schedule the OLFC,', 'allowing for the washout period for antihistamines, keeping in mind the difficulty for some', 'individuals during certain times of the year (eg, peak pollen season for rhinitis), and being', 'mindful of visit windows. Study site staff should inform the subject and parent/caregiver in', 'advance of the scheduled OLFC to communicate the following:', 'Review the events of the day (eg, study procedures, modality of the OLFC, possibility', 'of extended observation) and address any potential problems.', \"Confirm and document the appointment date and time in the subject's source\", 'documents.', 'Explain that the OLFC will be rescheduled in case of illness or symptoms such as', 'wheezing, fever, vomiting, and diarrhea; the subject and parent/caregiver are to notify', 'the study site if such symptoms develop before the OLFC.', \"Establish that the subject's other atopic diseases (eg, asthma, eczema, rhinitis) are\", 'stable.', 'Instruct that the subject is to avoid antihistamines and other current medications that', 'may affect safety or interfere with the OLFC assessment for 5 half-lives of the', 'medication before the OLFC begins. Review the prescribing information to', \"determine the half-life of each medication for the subject's relevant age group.\", 'Instruct that food and fluids (except for water and clear liquids) are to be withheld for', '2 hours before the OLFC.', 'Instruct the subject to withhold the dose of study product on the day of the OLFC.', \"Determine the subject's preference/tolerance for the foods that may be used for the\", 'OLFC (chocolate or vanilla pudding, or applesauce). Identify foods that must not be', 'used for masking the product tested due to allergy.', 'On the Day of the OLFC', '1. Check the protocol schedule of activities and complete any required procedures as', 'specified before starting the OLFC.', '2. Confirm the following:', 'Subject has not administered study product.', 'Negative urine pregnancy test for all female subjects of childbearing potential.', 'No recent or active illnesses. Reschedule the OLFC if the subject is experiencing', 'symptoms of an acute infection (eg, fever, recent nausea, vomiting, diarrhea) or any', \"other illness that may interfere with the subject's safety or interpretation of the\", 'results. Do not conduct the OLFC if illness is suspected.', 'Control of chronic atopic diseases. Do not proceed with the OLFC if the subject is', 'experiencing unstable or exacerbated atopic disease such as asthma, atopic dermatitis,']\n\n###\n\n", "completion": "END"}